Dear colleagues, Dear friends,
As many of you know, the Santorini Conference Series have been founded in 2000 on the initiative of Professor Gerard Siest (┼, INSERM UMR U1122; IGE-PCV, University of Lorraine, Nancy, France, click here on to see video in memory of Gerard Siest) and several representatives of industrial companies with the intention to create an independent and open platform to mediate “translation” in personalised medicine.
Based on the history and tradition of the previous Santorini Conferences, a new era of these conferences has started in October 2016 under my Presidency and it was a great pleasure to welcome a number of you at the 8th Santorini Conference, Oct. 3-5 2016.
The event was highly interactive, with much communication among the broad mix of attendees (researchers, scientists, academics, industrials, biologists, pathologists, oncologists, genetic epidemiologists, pharmacogeneticists and biobanking experts). It contained sessions on various topics on up-to-the-minute personalised medicine, genomics and pharmacogenomics tools and prospective health systems biology, with an interactive round table added to the mix where barriers to the integration of personalised medicine and the most urgent actions that need to be taken were discussed, as well as an oral communication session, workshops organised by ESPT and MSCA-RISE-2015 MAST4HEALTH, and social events with high participation of attendees.
The scientific program lived up to our expectations! The attendance reached over 140 participants from 33 different countries.
We created special poster awards in the memory of Gérard Siest and we were able to attribute 2 posters with the help of the University of Lorraine and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
It is now time to save the date for our next Conference, the 9th Santorini Conference, to be held next year from 30 September to 3 October 2018 in the same location as the last one.
Together with a Steering Committee (SC) and Scientific Advisory Board (SAB) with members across academia, clinics and industry, the 9th Santorini Conference will be part of a new era of the conferences.
The goal to facilitate scientific exchange between basic research, industrial research and medical areas has been maintained and strengthened by a sustainable and clearly visible new concept with respect to content, structure, economy and people.
The main title remains somewhat the same but dealing with Greek mythology in the spirit of the island and of our thematic obstacles to resolve and overcome:
Systems Medicine, Personalised Health & Therapy. “The Odyssey from Hope to Practice” with a special focus on “cardio-metabolic diseases and cancer”.
We already took into account important remarks made by some of last conference participants to improve the organisation of the 9th Conference by creating more interactions among disciplines, as well as between academic and industrial research, directed around a scientific content towards an effective ‘roadmap’ for personalised health and therapy.
The scientific programme includes morning sessions, starting from 9:00 am and finishing at 2:00 pm, with a coffee break of 1/2 hour and 1/2 hour for posters visit. Evening sessions (starting the 30th of September with the opening lecture) will be held from 5:00 pm to 7:00 pm. The programme includes 1 session with young researchers’ lectures. The 2 best posters will be granted with “Gerard Siest” awards.
The 9th Conference aims to answer:
- Can genetic screening help identify individuals at greatest risk for cardio-metabolic diseases and cancer?
- What is the greatest clinical need with regard to diagnosis, prediction and patient stratification for these pathologies and how this is/can be addressed?
- Does a genetic risk score identify patients at highest risk and is its use justified in clinical practice?
- What are the challenges of the current clinical trials?
- What about comorbidities with aging?
- What is the impact of pharmacogenomics on:
- Deliverance of more predictable responses to drug therapy
- Minimisation of the occurrence and severity of adverse drug reactions
- Conduction of more cost-effective clinical trials
- Drug discovery and the drug development process
- Do the existing diagnostic tools answer the needs of pharmacogenomics?
A more detailed program will be soon available on this website, but you can already note the dates (30 September to 3 October 2018) on your calendar and plan to join us and help make this 9th event a real success.
This conference will be also yours and we count on you for having your ideas/propositions and for being with us in Santorini in 2018 under a nice sun and warm weather that fosters an even more creative atmosphere!
President of the Santorini Conference series